The FDA just says yes.
Will a new and, some say, improved FDA improve the conditions, financial and otherwise, of patient care? Many argue that the acceleration of the FDA approval process comes at a high price. As new drugs hit the market faster--and with less proof of their long-term benefits--health care costs are going up, up, up, and society is facing painful rationing decisions.
MacPherson
P
P
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D003254:Consumer Advocacy; D017277:Drug Approval / Q000191:economics*; D016527:Drug Costs; D015507:Drugs, Investigational / Q000191:economics / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D008329:Managed Care Programs; D008484:Medicaid; D013221:State Health Plans; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration*
D015507:Drugs, Investigational